Ironwood Pharmaceuticals (NASDAQ:IRWD) Now Covered by Analysts at Piper Sandler

Investment analysts at Piper Sandler began coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) in a research report issued to clients and investors on Friday, The Fly reports. The firm set an “overweight” rating on the biotechnology company’s stock.

IRWD has been the subject of a number of other research reports. TheStreet upgraded Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, January 19th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $14.33.

Shares of IRWD stock opened at $11.78 on Friday. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 3.65 and a beta of 1.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.61 and a quick ratio of 4.61. The business has a fifty day moving average of $11.84 and a 200 day moving average of $11.89. Ironwood Pharmaceuticals has a 1 year low of $10.13 and a 1 year high of $14.27.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last issued its earnings results on Thursday, February 17th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.31 by ($0.04). The firm had revenue of $117.13 million during the quarter, compared to analysts’ expectations of $110.18 million. Ironwood Pharmaceuticals had a return on equity of 42.43% and a net margin of 127.72%. The business’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the business earned $0.36 EPS. As a group, equities research analysts expect that Ironwood Pharmaceuticals will post 1.47 earnings per share for the current year.

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 3,031 shares of the business’s stock in a transaction that occurred on Thursday, March 24th. The stock was sold at an average price of $12.75, for a total value of $38,645.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.60% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of IRWD. Point72 Hong Kong Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the third quarter worth $43,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth $63,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Ironwood Pharmaceuticals during the third quarter worth $83,000. Advisor Group Holdings Inc. grew its stake in shares of Ironwood Pharmaceuticals by 267.6% during the third quarter. Advisor Group Holdings Inc. now owns 8,143 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 5,928 shares in the last quarter. Finally, Financial Counselors Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $117,000.

About Ironwood Pharmaceuticals (Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Read More

The Fly logo

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.